EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhanced Fc and complement activity of Fc‐modified avelumab boosts anti‐tumor activity but promotes NK cell fratricide

Lachlan J Dobson iD, Barry D Hock, Ariana Ht Drabble, Liping Goddard, Judith L McKenzie, Sean A MacPherson, Alexander D McLellan iD

Clinical & Translational Immunology · 2026-05 · 15 (5)

DOI: 10.1002/cti2.70098 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Translational Immunology, online erschienen am 05.05.2026. Verfasst von Lachlan J Dobson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology University of Otago Dunedin New Zealand. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Council of New Zealand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The anti‐PD‐L1 antibody avelumab has demonstrated efficacy across multiple cancer types. Avelumab primarily blocks the PD‐1/L1 immune checkpoint, while inducing antibody‐dependent cellular cytotoxicity (ADCC) from CD16a + NK cells. However, subsets of patients possess lower‐affinity CD16a allotypes that limit ADCC capacity of monoclonal antibodies. In this study, we modified the Fc domain of avelumab with characterised mutations to enhance ADCC across all CD16a allotypes.

Methods

Comparisons between the wild‐type avelumab and modified ‘AveFc5M’ were carried out to assess the impacts of introduced mutations on PD‐L1 blockade, ADCC induction and complement‐dependent cytotoxicity (CDC) induction. To assess ADCC, a range of PD‐L1 + target cells were coated with mab prior to incubation with effector cells, with both high‐ and low‐affinity CD16a allotypes represented. Human serum was employed for assessing CDC.

Results

Both antibodies exhibited equivalent PD‐L1 blocking activity. Notably, the modified AveFc5M displayed significantly enhanced ADCC across diverse tumor cell–effector cell combinations. Fc mutations also conferred the ability to mediate complement‐dependent cytotoxicity (CDC) against a PD‐L1 + lymphoma cell line. However, short term activation of NK cells or long‐term expansion on artificial antigen presenting cells, led to upregulation of PD‐L1 on NK cells. Addition of avelumab or AveFc5M to these NK cell populations induced a marked reduction in viable NK cells via ADCC‐mediated fratricide.

Conclusion

These findings demonstrate that Fc engineering of avelumab can substantially augment ADCC and CDC activity against PD‐L1 + tumors. However, the enhanced effector function of AveFc5M led to NK cell fratricide, potentially limiting NK cell‐dominated anti‐cancer responses.

Schlagwörter

Stichwörter der Autor:innen

antibody‐dependent cellular cytotoxicitycomplement‐dependent cellular cytotoxicityimmune checkpoint inhibitormonoclonal antibodies

Autor:innen und Institutionen

  • Department of Microbiology and Immunology University of Otago Dunedin New Zealand.
  • Haematology Research Group, Department of Pathology and Biomedical Science University of Otago Christchurch New Zealand.
  • Haematology Department Christchurch Hospital Christchurch New Zealand.
  • Department of Histology, Faculty of Medicine University of Indonesia Jakarta Indonesia.

ORCID-Profile: Lachlan J Dobson, Alexander D McLellan

Förderung

  • Health Research Council of New Zealand

Zitieren

APA

Dobson, L. J., Hock, B. D., Drabble, A. H., Goddard, L., McKenzie, J. L., MacPherson, S. A., & McLellan, A. D. (2026). Enhanced Fc and complement activity of Fc‐modified avelumab boosts anti‐tumor activity but promotes NK cell fratricide. Clinical & Translational Immunology, 15(5). https://doi.org/10.1002/cti2.70098

Vancouver

Dobson LJ, Hock BD, Drabble AH, Goddard L, McKenzie JL, MacPherson SA, et al. Enhanced Fc and complement activity of Fc‐modified avelumab boosts anti‐tumor activity but promotes NK cell fratricide. Clinical & Translational Immunology. 2026;15(5). doi:10.1002/cti2.70098

BibTeX
@article{Dobson2026,
  author = {Dobson, Lachlan J and Hock, Barry D and Drabble, Ariana Ht and Goddard, Liping and McKenzie, Judith L and MacPherson, Sean A and McLellan, Alexander D},
  title = {Enhanced Fc and complement activity of Fc‐modified avelumab boosts anti‐tumor activity but promotes NK cell fratricide},
  journal = {Clinical & Translational Immunology},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/cti2.70098}
}
Kostenlos starten →